Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
Goal of Serum Institute of India Limited (SIIL) is the development of a recombinant urease
 C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated
 and efficacious vaccine against tuberculosis (TB) for residents in endemic areas and persons
 at risk in non-endemic areas. The new vaccine should be at least as potent as the current
 strain and should be safer than BCG.

 The preceding phase-IIa trial was the first investigation of VPM1002 in newborn infants in a
 high burden setting in South Africa. The vaccination of HIV-unexposed infants with VPM1002
 indicated again safety, tolerability and immunogenicity sufficient to proceed in HIV-exposed
 infants.

 The current study is a multiple site trial in South Africa to evaluate safety and
 immunogenicity in HIV-unexposed and -exposed newborn infants.
Inclusion Criteria:

 Maternal:

 1. The infant's mother must be aged 18 years or older at screening.

 2. The infant's mother must be able and willing to comply with the study protocol,
 available and willing to allow her child to complete all the study assessments and
 must have signed an Informed Consent form that has been approved by all relevant
 Ethics Committee/s.

 3. The infant's mother must not have any symptoms or signs of active TB as indicated by
 history of cough for more than two weeks, fever, weight loss, breathlessness, chest
 pain, blood in sputum, night sweats and loss of appetite

 4. The infant's mother should not be planning to relocate from the research site area and
 should be reachable by phone during the whole study period i.e. for the 12 months
 on-study period as well as the 24 month structured medical surveillance period.

 5. For HIV-unexposed group: The infant's mother must test negative for HIV-1 (ELISA 4th
 generation) within the period from 2 weeks prior to the infant's birth to vaccination
 of the infant with the investigational product.

 For the HIV-exposed group: The infant's mother must test positive for HIV-1 (ELISA 4th
 generation) within the period from 2 weeks prior to the infant's birth to vaccination
 of the infant with the investigational product. The infant's mother must have enrolled
 for standard antiretroviral therapy (ART) at least 3 months before the participating
 infant's birth and must have a viral load at screening below 1000 copies/ml. The use
 of ART, including combination antiretroviral therapy (cART) and preventive mother to
 child transmission (PMTCT) must be documented. CD4+ T cell count and HIV viral load
 must be documented.

 6. The infant's mother must test negative for Hepatitis B and syphilis serology at
 screening.

 7. The infant's mother should have no history or evidence of diabetes mellitus.

 8. No participation of the infant's mother in a clinical trial within 3 months prior to
 the birth of the participating infant. In addition, if breast-feeding, no
 participation in another clinical trial during the 12 months of the current study.

 9. The infant's mother must have no known history of immunodeficiency, except for HIV.

 Infant:

 1. Healthy male or female newborn infants aged 0 to 12 days.

 2. Infants must have a birth weight of 2500 - 4200 g and an Apgar score of > 7 at 5
 minutes or earlier.

 3. No eczema or other significant skin lesion or infection at the intended injection
 site.

 4. No routine BCG vaccination administered (as per vaccination record)

 5. Infants must receive Oral Polio Vaccine as part of the routine South African Expanded
 Programme on Immunisation (EPI) Childhood Immunisation schedule, and must adhere to
 the subsequent EPI schedule for the entire study period, except for the BCG
 vaccination at birth.

 6. No participation of the infant in another clinical trial before study vaccination and
 during the 12 months of the current study.

 Exclusion Criteria:

 Maternal:

 1. Known presence of any person in the household of the mother and newborn infant, or any
 recent visitor to the household with recently diagnosed, active tuberculosis disease
 (within last 3 months).

 2. Treatment of the mother with blood products in the 6 months prior to or during the
 birth of the participating infant.

 3. For the HIV-unexposed group: Positive test for HIV-1 either during the current
 pregnancy or at screening.

 For the HIV-exposed group: Negative test for HIV-1 either during the current pregnancy
 or at screening.

 4. Presence of signs or symptoms of any reported acute infectious disease at the time of
 screening.

 5. Any reported or suspected substance abuse.

 Infant:

 1. History or evidence of any systemic disease on physical examination or any acute,
 chronic or intercurrent illness that, in the opinion of the investigator, may
 interfere with the evaluation of the safety or immunogenicity of the vaccine.

 Note: Neonatal jaundice not considered clinically significant by the investigator is
 not an exclusion.

 2. Fever within the period post birth and prior to dosing. For the purposes of this
 protocol, fever in the infant will be defined as an axillary body temperature > 38.0°C
 measured by digital thermometer on at least 2 occasions not less than 6 hours apart.

 3. Hypothermia within the period post birth and prior to dosing. For the purposes of this
 protocol, hypothermia in the infant will be defined as an axillary body temperature <
 36.0°C measured by digital thermometer on at least 2 occasions not less than 6 hours
 apart.

 4. Clinically suspected newborn sepsis.

 5. Any malignant condition.

 6. Any severe congenital malformation.

 7. Concomitant treatment with medication that may significantly affect immune function
 (e.g. systemic corticoids, immunosuppressive drugs) before study vaccination.
 Antibiotics given before study vaccination would further constitute exclusion.

 8. Treatment of the infant with blood products.